Why Are You Using a Generalist Agency for Specialized Oncology Roles?

Your next VP Business Development isn't browsing LinkedIn. Your ideal CMO isn't submitting applications. The executives who can transform your biotech are currently leading programs at Roche, Novartis, and AstraZeneca—and we know them.

Request Confidential Call

A Bad Hire Costs Millions and 12 Months You Can't Get Back

When you're racing toward an IND submission, preparing for a Series C raise, or building toward a Phase 2 trial, hiring the wrong executive is catastrophic.

Problem 1:

3 months to realize they're not working out

Wrong therapeutic expertise, can't navigate FDA, doesn't build team chemistry.

Problem 2:

3 months to exit them properly Performance management, documentation, legal process, severance negotiations.

Problem 3:

6 months to find a replacement New search process, interviews, reference checks, notice periods.

Total: 12 months lost.

Clinical timelines delayed. Team demoralized. Investors questioning leadership.

In oncology biotech, you don't get do-overs.

OUR SOLUTION CLICK HERE

Our Oncology Sub-Specialties

We don't do "general life sciences." We focus exclusively on two oncology areas where innovation is accelerating.

Immuno-Oncology

Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
CAR-T & Cell Therapies
NK Cell Engagers
Bispecific Antibodies
Cancer Vaccines (mRNA & traditional)
IO Combination Strategies
Tumor Microenvironment Modulation

More info

Physician and Patient Analyze a Holographic Body Model. Technology Discussions on Optimizied Health Care, Diagnostic Accuracy. Personalized Treatment Approaches In A Futuristic Healthcare Environment

AI Oncology

AI Drug Discovery
Machine Learning for targets
Computational Biology
AI Diagnostics & Pathology
Clinical trial optimization
Predictive modeling
Bioinformatics

More info

Precision Medicine & Diagnostics

Liquid Biopsy & ctDNA Testing
Companion Diagnostics (CDx)
Minimal Residual Disease (MRD) Monitoring
Comprehensive Genomic Profiling (CGP)
Targeted Therapies (EGFR, ALK, BRCA, etc.)
AI-Driven Genomic Analysis
Biomarker-Driven Trial Design

More info

Gold star on a blue background as a reward. Top Performance Award. Winners Cup. Achievements. Victory. Goal achievement concept. Winner certificate. First place in a computer game. 3D rendering.

C-Suite & Board

Chief Medical Officer (CMO)
Chief Scientific Officer (CSO)
Chief Development Officer (CDO)
Board Members (Oncology Expertise)
Scientific Advisory Board

Clinical & Regulatory

VP Clinical Development
VP Regulatory Affairs
Head of Clinical Operations
Medical Directors (Oncology)
VP Translational Medicine
Head of Biostatistics

Digital genetics doctor in the era of precision medicine.

Medical Affairs & Commercial

VP Medical Affairs
Medical Directors
VP Oncology Sales
VP Market Access & Reimbursement
Head of HEOR (Health Economics)
VP Commercial Strategy

Where We Find Your Next Executive

Slide 1 of 7

Code of ethics symbol. Concept words Code of ethics on wooden blocks.Business and Code of ethics concept. Copy space.3D rendering on blue background.

Primary Sources (500+ Network): Big Pharma 4 (Oncology Division Leaders): Roche Oncology (Basel, South San Francisco) Novartis Oncology (Basel, Cambridge) AstraZeneca Oncology (Cambridge UK, Gaithersburg) Bristol Myers Squibb Oncology (Princeton)

Why These Companies? Proven IO, ADC, and precision medicine programs Executives understand late-stage clinical development They've launched products and navigated FDA They bring KOL networks and regulatory credibility

The concept of coherence and coordination.

Secondary Sources: Series C/D biotechs (executives ready for next challenge) Academic oncology (KOL clinicians transitioning to industry) Consulting/advisory (ex-pharma executives)

Geographic Focus: Primary: UK, Switzerland, USA (East Coast) Secondary: USA (West Coast), Germany, France

Primary Focus (70% of placements): VP/Director Business Development Partnerships, licensing, out-licensing deals Pharma relationship management $50M-500M+ deal experience

Binary code behind a blue digital fingerprint

Secondary Focus (30% of placements): VP Clinical Development (Phase 2/3 trial leaders) VP Regulatory Affairs (BLA/MAA experts) Head of Medical Affairs VP Commercial Strategy (pre-launch)

Businessman using digital interface to review candidate profiles and select the right person. AI recruitment, resume screening, HR technology, data-driven human resource management.

What We DON'T Do: Commercial sales roles (reps, MSLs) Early R&D (discovery, translational science) Non-oncology positions

Primary Sources (500+ Network): Big Pharma 4 (Oncology Division Leaders): Roche Oncology (Basel, South San Francisco) Novartis Oncology (Basel, Cambridge) AstraZeneca Oncology (Cambridge UK, Gaithersburg) Bristol Myers Squibb Oncology (Princeton)

Why These Companies? Proven IO, ADC, and precision medicine programs Executives understand late-stage clinical development They've launched products and navigated FDA They bring KOL networks and regulatory credibility

Secondary Sources: Series C/D biotechs (executives ready for next challenge) Academic oncology (KOL clinicians transitioning to industry) Consulting/advisory (ex-pharma executives)

Geographic Focus: Primary: UK, Switzerland, USA (East Coast) Secondary: USA (West Coast), Germany, France

Primary Focus (70% of placements): VP/Director Business Development Partnerships, licensing, out-licensing deals Pharma relationship management $50M-500M+ deal experience

Secondary Focus (30% of placements): VP Clinical Development (Phase 2/3 trial leaders) VP Regulatory Affairs (BLA/MAA experts) Head of Medical Affairs VP Commercial Strategy (pre-launch)

What We DON'T Do: Commercial sales roles (reps, MSLs) Early R&D (discovery, translational science) Non-oncology positions

Primary Sources (500+ Network): Big Pharma 4 (Oncology Division Leaders): Roche Oncology (Basel, South San Francisco) Novartis Oncology (Basel, Cambridge) AstraZeneca Oncology (Cambridge UK, Gaithersburg) Bristol Myers Squibb Oncology (Princeton)

Why These Companies? Proven IO, ADC, and precision medicine programs Executives understand late-stage clinical development They've launched products and navigated FDA They bring KOL networks and regulatory credibility

Secondary Sources: Series C/D biotechs (executives ready for next challenge) Academic oncology (KOL clinicians transitioning to industry) Consulting/advisory (ex-pharma executives)

Geographic Focus: Primary: UK, Switzerland, USA (East Coast) Secondary: USA (West Coast), Germany, France

Primary Focus (70% of placements): VP/Director Business Development Partnerships, licensing, out-licensing deals Pharma relationship management $50M-500M+ deal experience

Secondary Focus (30% of placements): VP Clinical Development (Phase 2/3 trial leaders) VP Regulatory Affairs (BLA/MAA experts) Head of Medical Affairs VP Commercial Strategy (pre-launch)

What We DON'T Do: Commercial sales roles (reps, MSLs) Early R&D (discovery, translational science) Non-oncology positions

Get in touch

Send us a message and we'll get back to you as soon as we can.